Comparative Pharmacology
Head-to-head clinical analysis: CYTOTEC versus ZIOPTAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYTOTEC versus ZIOPTAN.
CYTOTEC vs ZIOPTAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Misoprostol is a synthetic prostaglandin E1 analog that binds to prostanoid receptors, leading to inhibition of gastric acid secretion (both basal and stimulated) and increased mucus and bicarbonate secretion, providing mucosal protection. Additionally, it stimulates uterine contractions and cervical ripening.
ZIOPTAN (tafluprost) is a prostaglandin analog that reduces intraocular pressure by increasing the outflow of aqueous humor through the uveoscleral pathway.
200 mcg orally four times daily with food for prevention of NSAID-induced gastric ulcers. For termination of pregnancy: 800 mcg vaginally every 12-24 hours or 600 mcg orally as a single dose.
250 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life of misoprostol acid is approximately 20-40 minutes. Due to rapid de-esterification, the half-life of the prodrug is very short (<5 minutes). No accumulation occurs with repeated dosing. In patients with renal impairment, half-life may be prolonged (up to 80 minutes) and dose adjustment may be necessary.
Terminal elimination half-life is approximately 2.8 to 4.5 hours in patients with normal renal function; no clinically significant accumulation occurs with twice-daily dosing.
Following oral administration, misoprostol is rapidly de-esterified to misoprostol acid, the active metabolite. Renal excretion of misoprostol acid is approximately 64-73% of the dose (with 11-17% as unchanged acid) over 24 hours. Fecal excretion accounts for about 15% of the dose, primarily as metabolites. Biliary excretion is minimal. The remainder is eliminated as unidentified metabolites.
Primarily renal excretion of unchanged drug (approximately 70-80% of an administered dose recovered in urine over 48 hours); biliary/fecal excretion accounts for 13% to 20% as parent drug and metabolites.
Category C
Category C
Prostaglandin Analog
Prostaglandin Analog